Dr. Scheller has served as a member of our Board since March 2015. Dr. Scheller was Chief Scientific Officer and Head of Therapeutics at 23andMe, a personal genetics company, from 2015 to 2019, when he retired and joined its board of directors. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd. In addition to serving on the board of directors of 23andMe, Dr. Scheller currently serves as a member of the board of directors of Alector, Inc. (since October 2018), BridgeBio Inc. (since January 2018), and ORIC Pharmaceuticals, Inc. (since February 2015). Dr. Scheller has also served as the chair of the board of directors at DiCE Molecules SV, LLC since late 2015. He is a former member of the board of directors for Affinita Biotech, Inc. and Medrio, Inc. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University.